SCHEMBL23527004

SCHEMBL23527004

COc1ccc(OC2CCN(c3c(C#N)c(=O)n(C)c4ccc(Cl)nc34)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ DGKA P23743 3/20 0.46
▸ DGKZ Q13574 3/20 0.46
▸ ALDH1A1 P00352 2/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ KDM1A O60341 1/20 0.38
▸ HRH3 Q9Y5N1 6/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ CHRM4 P08173 2/20 0.37
▸ KCNH2 Q12809 4/20 0.37
▸ SCD O00767 2/20 0.36
▸ ADRA1A P35348 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ GRM2 Q14416 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ FPR2 P25090 1/20 0.35
▸ PROKR1 Q8TCW9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31133736 1.00 DGKA (0.46) DGKADGKZALDH1A1NPSR1KDM1A
SCHEMBL31133750 0.94 DGKA (0.52) DGKADGKZALDH1A1HRH3CHRM4
SCHEMBL31133650 0.94 DGKA (0.46) DGKADGKZHRH3CHRM4KCNH2
SCHEMBL23527176 0.94 DGKA (0.52) DGKADGKZALDH1A1HRH3CHRM4
SCHEMBL23527307 0.94 DGKA (0.46) DGKADGKZHRH3CHRM4KCNH2
SCHEMBL23527095 0.93 HRH3 (0.47) DGKADGKZKDM1AHRH3FPR2
SCHEMBL31133498 0.93 HRH3 (0.47) DGKADGKZKDM1AHRH3FPR2
SCHEMBL23527042 0.92 DGKA (0.45) DGKADGKZHRH3CHRM4SCD
SCHEMBL31133628 0.92 DGKA (0.45) DGKADGKZHRH3CHRM4SCD
SCHEMBL23526862 0.92 DGKA (0.47) DGKADGKZHRH3CHRM4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081523-B1 SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2024-12-25 — — EP claimed
US-11964973-B2 Substituted bicyclic compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2024-04-23 — — US claimed
WO-2021133750-A1 SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-07-01 — — WO claimed
US-20210188845-A1 SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY 2021-06-24 — — US claimed
EP-4081523-B1 SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2024-12-25 — — EP disclosed
US-11964973-B2 Substituted bicyclic compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2024-04-23 — — US disclosed
WO-2021133750-A1 SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-07-01 — — WO disclosed
US-20210188845-A1 SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY 2021-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188845-A1 SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKA, DGKZ, DGKK DGKA 1/4885DGKZ 2/4885ALDH1A1 4765/4885
US-11964973-B2 Substituted bicyclic compounds useful as T cell activators DGKA, DGKZ, DGKK DGKA 1/4885DGKZ 2/4885ALDH1A1 4765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback